Posts tagged epilepsy
Maxim starts Zynerba Pharma at buy

Maxim Group initiated coverage of Zynerba Pharmaceuticals (NASDAQ:ZYNE) with a “buy” rating and 12-month price target of $32. The stock closed at $22.10 on Feb. 23.

Read More
Stifel starts Xenon Pharma at buy

Stifel initiated coverage of Xenon Pharmaceuticals (NASDAQ:XENE) with a “buy” rating and $18 price target. The stock closed at $8.35 on Oct. 20.

Analyst Stephen Willey writes that Xenon has successfully leveraged its Extreme Genetics drug discovery platform, which identifies single-gene defects responsible for severe human phenotypes, into a maturing pipeline of both partnered and wholly-owned product candidates on the precipice of achieving proof-of-concept inflection points.

Read More
Corey Davis joins HCW’s research team

Corey Davis has joined H.C. Wainwright in equity research as a managing director, covering specialty pharmaceuticals.

Dr. Davis has 19 years of sell-side experience, covering specialty pharmaceutical companies, spending most of those years at JP Morgan and Jefferies. 

Read More